Lomitapide (DB08827): A Comprehensive Pharmacological and Clinical Monograph for the Management of Homozygous Familial Hypercholesterolemia

Introduction and Drug Profile

Overview and Therapeutic Context

Lomitapide is a first-in-class, orally administered small molecule inhibitor of the Microsomal Triglyceride Transfer Protein (MTP).[1] It represents a significant therapeutic innovation specifically developed as an adjunctive treatment for patients with Homozygous Familial Hypercholesterolemia (HoFH).[4] HoFH is a rare, life-threatening autosomal recessive or compound heterozygous genetic disorder of lipid metabolism characterized by a profound impairment or complete absence of low-density lipoprotein (LDL) receptor function.[6] This genetic defect leads to extremely elevated plasma concentrations of LDL-cholesterol (LDL-C) from birth, resulting in aggressive, premature atherosclerotic cardiovascular disease (ASCVD), often manifesting as major adverse cardiovascular events (MACE) in childhood, adolescence, or early adulthood.[7]

The defining therapeutic characteristic of Lomitapide is its novel mechanism of action, which is entirely independent of the LDL-receptor pathway.[9] Conventional lipid-lowering therapies, such as statins, primarily exert their effect by upregulating the expression of hepatic LDL receptors to enhance the clearance of circulating LDL particles. In HoFH patients, where these receptors are dysfunctional or absent, such therapies are often of limited efficacy.[6] Lomitapide circumvents this limitation by directly targeting the production of LDL precursors in the liver and intestine, thereby offering a potent LDL-C lowering effect in a patient population with a profound unmet medical need.

The drug was developed by Aegerion Pharmaceuticals and is marketed under the brand names Juxtapid in the United States and Lojuxta in the European Union.[1] Its development history reflects a strategic focus on rare diseases; initial exploration for broader hypercholesterolemia was discontinued in favor of concentrating on the HoFH indication, where its unique mechanism and potent efficacy could provide the greatest clinical benefit despite a challenging side effect profile.[9] The developmental codes associated with Lomitapide, including BMS-201038 and AEGR-733, point to its origins at Bristol-Myers Squibb before its acquisition and focused development by Aegerion Pharmaceuticals, a trajectory common for specialized orphan drugs that require a dedicated development program to bring them to a niche market.[2]

Chemical Identity and Physicochemical Properties

Lomitapide is a complex synthetic molecule, classified chemically as a member of the benzamides, piperidines, fluorenes, and (trifluoromethyl)benzenes.[1] Its structure is meticulously designed to enable potent and specific inhibition of its biological target. The drug is most commonly administered as a mesylate salt, Lomitapide Mesilate.[13] A comprehensive profile of its chemical and physical properties is essential for understanding its formulation, stability, and pharmacological behavior.

The formal International Union of Pure and Applied Chemistry (IUPAC) name for Lomitapide is N-(2,2,2-Trifluoroethyl)-9-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluoren-9-carboxamide.[4] Its molecular formula is

C39​H37​F6​N3​O2​, corresponding to a molecular weight of 693.73 g/mol.[1] In its solid state, Lomitapide is a white to almost white crystalline powder with a defined melting point of 142 °C.[1]

Its solubility characteristics are critical for its formulation and absorption. The mesylate salt is slightly soluble in aqueous solutions at acidic pH (pH 2 to 5) but is insoluble in heptane.[1] It demonstrates free solubility in several organic solvents, including acetone, ethanol, and methanol, and is soluble in 2-butanol, methylene chloride, and acetonitrile.[1] Lomitapide is heat sensitive and requires refrigerated storage (0-10°C) to ensure long-term stability.[15] The detailed chemical and physical identifiers for Lomitapide are consolidated in Table 1.

Table 1: Chemical and Physical Properties of Lomitapide

Property	Value	Source(s)
DrugBank ID	DB08827	4
Type	Small Molecule	5
CAS Number	182431-12-5 (Free Base)	4
	202914-84-9 (Mesylate Salt)	4
Brand Names	Juxtapid (US), Lojuxta (EU)	1
Developmental Codes	AEGR-733, BMS-201038, AEGR 773	2
IUPAC Name	N-(2,2,2-Trifluoroethyl)-9-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluoren-9-carboxamide	4
Chemical Formula	C39​H37​F6​N3​O2​	11
Molecular Weight	693.73 g/mol	1
Physical Appearance	White to almost white powder or crystal	1
Melting Point	142 °C	15
Solubility Profile	Slightly soluble in aqueous solutions (pH 2-5); Freely soluble in acetone, ethanol, methanol; Insoluble in heptane.	1
SMILES Code	O=C(NCC(F)(F)F)C1(C2=C(C=CC=C2)C3=C1C=CC=C3)CCCCN4CCC(CC4)NC(C5=CC=CC=C5C6=CC=C(C=C6)C(F)(F)F)=O	11
InChIKey	MBBCVAKAJPKAKM-UHFFFAOYSA-N	11

Preclinical and Clinical Pharmacology

Mechanism of Action: Potent MTP Inhibition

The therapeutic effect of Lomitapide is derived from its function as a potent, selective, and direct-binding inhibitor of the Microsomal Triglyceride Transfer Protein (MTP, also abbreviated as MTTP).[1] MTP is an intracellular lipid transfer protein located within the lumen of the endoplasmic reticulum, where it is abundantly expressed in two key cell types: hepatocytes in the liver and enterocytes in the small intestine.[3] In vitro assays have demonstrated the high potency of Lomitapide, with reported half-maximal inhibitory concentration (

IC50​) values ranging from 0.5 nM to 8 nM.[2]

MTP plays an indispensable role in the assembly and secretion of apolipoprotein B (ApoB)-containing lipoproteins, which are the primary carriers of triglycerides and cholesterol in the circulation.[3] Its function is to shuttle lipid molecules, primarily triglycerides but also cholesteryl esters and phospholipids, from the endoplasmic reticulum membrane to the nascent, elongating ApoB polypeptide chain.[3] This lipidation process is the rate-limiting step for the formation of mature, secretion-competent lipoprotein particles.

By binding directly to MTP, Lomitapide physically obstructs this lipid transfer process. This inhibition has two critical, tissue-specific consequences:

1. In the Liver: MTP is essential for the assembly of Very Low-Density Lipoproteins (VLDL), which contain the ApoB-100 isoform. By inhibiting hepatic MTP, Lomitapide blocks the formation and subsequent secretion of VLDL particles from hepatocytes into the bloodstream.[4] Since VLDL particles are the metabolic precursors of Intermediate-Density Lipoproteins (IDL) and, ultimately, Low-Density Lipoproteins (LDL), this reduction in VLDL production leads to a profound decrease in the circulating pool of LDL particles and their associated cholesterol content (LDL-C).[8]
2. In the Intestine: MTP is required for the assembly of chylomicrons, which contain the ApoB-48 isoform. Chylomicrons are responsible for packaging and transporting dietary fats (triglycerides) from the intestine into the lymphatic system and then the circulation. By inhibiting intestinal MTP, Lomitapide impairs chylomicron formation, thereby reducing the absorption of dietary fat.[3]

The LDL-receptor-independent nature of this mechanism is the cornerstone of Lomitapide's utility in HoFH. Unlike statins or PCSK9 inhibitors, which rely on functional LDL receptors to clear lipoproteins from the blood, Lomitapide works "upstream" by reducing the rate of lipoprotein production.[7] This makes it effective even in patients with null-receptor mutations who have no residual LDL receptor activity. The biological plausibility of this mechanism is strongly corroborated by the rare human genetic disorder abetalipoproteinemia, which is caused by loss-of-function mutations in the gene encoding MTP. Individuals with this condition have a near-total absence of ApoB-containing lipoproteins (VLDL, LDL, chylomicrons) in their plasma, mirroring the pharmacological effect of Lomitapide.[3]

Pharmacodynamics

The pharmacological inhibition of MTP by Lomitapide translates into a broad and profound impact on the plasma lipid profile. The primary pharmacodynamic effect is a significant, dose-dependent reduction in the concentrations of all ApoB-containing lipoproteins.[3] This leads to marked decreases in several key atherogenic lipid parameters, including LDL-C, total cholesterol (TC), apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TGs).[2]

Preclinical studies in various animal models provided the foundational evidence for this activity. In a hypertriglyceridemia model in Zucker fatty rats, single oral doses of Lomitapide at 0.3 mg/kg and 1 mg/kg reduced triglyceride secretion rates by 35% and 47%, respectively.[2] In hamsters, Lomitapide reduced total plasma cholesterol with a median effective dose (

ED50​) of 2.4 mg/kg.[16] Furthermore, in the Watanabe-heritable hyperlipidemic (WHHL) rabbit, an established animal model for HoFH, a 10 mg/kg dose of Lomitapide effectively decreased plasma cholesterol and triglyceride levels, demonstrating its efficacy in a setting of LDL-receptor deficiency.[16]

These preclinical findings were definitively confirmed in human studies. Lipoprotein kinetic studies performed in three HoFH patients treated with Lomitapide revealed a 70% reduction in the production rate of ApoB, directly validating the proposed mechanism of action in the target population.[3] These studies also confirmed that Lomitapide has no clinically significant direct effect on High-Density Lipoprotein (HDL) cholesterol, its major apolipoprotein ApoA-I, or lipoprotein(a) [Lp(a)] levels.[3] The drug's effect is specifically targeted to the ApoB-lipoprotein production pathway. In recent preclinical research, Lomitapide has also been shown to directly inhibit mTORC1 and induce autophagy-dependent cell death in cancer cell lines, suggesting potential off-target effects that warrant further investigation, though this is currently outside its clinical scope.[11]

Pharmacokinetics (ADME)

The pharmacokinetic profile of Lomitapide, encompassing its absorption, distribution, metabolism, and elimination (ADME), is characterized by low oral bioavailability, extensive tissue distribution, primary reliance on CYP3A4-mediated metabolism, and a long terminal half-life that supports once-daily dosing.

Absorption: Following oral administration, Lomitapide is absorbed with a time to maximum plasma concentration (Tmax​) of approximately 6 hours in healthy volunteers after a single 60 mg dose.[5] However, its absolute oral bioavailability is low, estimated to be only about 7%.[5] This low bioavailability is indicative of extensive first-pass metabolism in the gut wall and liver. The drug exhibits dose-proportional pharmacokinetics for oral single doses ranging from 10 mg to 100 mg.[17]

Distribution: Lomitapide is widely distributed throughout the body, as evidenced by its large mean volume of distribution at steady state, which ranges from 985 to 1292 L.[5] This suggests significant partitioning into tissues outside of the plasma compartment. It is also highly bound to plasma proteins, with a protein binding of approximately 99.8%, meaning only a very small fraction of the drug is free and pharmacologically active in the circulation at any given time.[5]

Metabolism: Lomitapide undergoes extensive metabolism, primarily in the liver.[2] The principal metabolic pathway is mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme.[1] Key metabolic reactions include oxidation, oxidative N-dealkylation, glucuronide conjugation, and opening of the piperidine ring.[17] This process leads to the formation of two primary plasma metabolites, designated M1 and M3. These metabolites have been shown to be pharmacologically inactive, meaning they do not contribute to the MTP-inhibitory effect of the drug.[3] While CYP3A4 is the major enzyme responsible, minor metabolic contributions from other CYP enzymes, including CYP1A2, CYP2B6, CYP2C8, and CYP2C19, have also been identified.[1] Other identified metabolites include M4 and M11.[19]

Elimination: The elimination of Lomitapide and its metabolites occurs through both renal and fecal routes. Following administration, more than 50% of the dose is excreted in the urine, predominantly as the M1 metabolite.[3] Approximately 33% to 35% of the dose is excreted in the feces, with unchanged Lomitapide being the main component found in stool.[3] The mean terminal elimination half-life of Lomitapide is approximately 39.7 hours, a relatively long duration that allows for effective plasma concentrations to be maintained with a once-daily dosing regimen.[2]

The pharmacology of Lomitapide presents a clear example of how a drug's core mechanism can be both its greatest strength and its primary liability. The potent inhibition of MTP in both the liver and the gut is a "double-edged sword." In the liver, this action powerfully reduces VLDL production, achieving the desired therapeutic goal of lowering LDL-C in patients who lack functional LDL receptors.[10] This is the intended and highly beneficial outcome. However, this same on-target mechanism has direct and predictable adverse consequences. The triglycerides that are blocked from being exported from hepatocytes accumulate within the cells, leading directly to hepatic steatosis, the basis for the drug's most serious safety concern and its boxed warning for hepatotoxicity.[3] Simultaneously, in the intestine, the inhibition of MTP prevents the formation of chylomicrons needed for dietary fat absorption.[3] The unabsorbed fat remaining in the gastrointestinal lumen directly causes the highly prevalent and often dose-limiting side effects of diarrhea, steatorrhea, and abdominal discomfort.[3] Thus, the main safety challenges of Lomitapide are not idiosyncratic or off-target effects but are direct, mechanism-based consequences of its therapeutic action, making them largely unavoidable and central to the drug's management strategy.

Furthermore, the pharmacokinetic profile creates a state of high vulnerability to drug-drug interactions. The combination of low oral bioavailability (~7%) and near-total reliance on CYP3A4 for clearance makes Lomitapide exceptionally sensitive to any medications that alter CYP3A4 activity.[5] The low bioavailability suggests that a large fraction of an oral dose is eliminated by first-pass metabolism in the gut wall and liver, where CYP3A4 is highly concentrated. Inhibition of this enzyme can therefore lead to a disproportionately large, and potentially toxic, increase in systemic drug exposure. This explains the stringent contraindication against using Lomitapide with moderate or strong CYP3A4 inhibitors and the mandatory 50% dose reduction required even with weak inhibitors.[10] This elevates medication reconciliation from a routine task to a critical, non-negotiable safety procedure for any patient being considered for Lomitapide therapy.

Clinical Efficacy in Homozygous Familial Hypercholesterolemia

Early Clinical Development

The clinical development pathway for Lomitapide was characterized by a strategic refinement of its target indication. Initially, the drug was investigated for the treatment of moderate to severe hypercholesterolemia in the general patient population.[9] A series of Phase 2 clinical trials, including NCT00690443, NCT00474240, and NCT00405067, evaluated the safety and efficacy of Lomitapide as a monotherapy and in combination with other standard lipid-lowering agents such as atorvastatin and ezetimibe.[22]

While these early studies demonstrated lipid-lowering efficacy, the fixed-dose regimens tested (ranging from 25 mg/d to 100 mg/d) were associated with a high incidence of dose-limiting adverse events.[9] The primary challenges were gastrointestinal intolerance and elevations in hepatic aminotransferases, which led to high rates of treatment discontinuation in this broader patient population.[9] Recognizing that the risk-benefit profile was not favorable for general use, the developers made a pivotal decision to halt development for this indication. Instead, they strategically pivoted to focus exclusively on the HoFH population, a group with a life-threatening condition and few effective treatment options, where the profound efficacy of Lomitapide would more clearly outweigh its significant tolerability and safety challenges.[9] This shift allowed for a more tailored development program focused on the specific needs and risk tolerance of patients with this rare and severe disease.

Pivotal Phase 3 Trial in Adult HoFH (NCT00730236)

The cornerstone of Lomitapide's regulatory approval was a multicenter, single-arm, open-label Phase 3 clinical trial (NCT00730236) designed to evaluate its efficacy and safety in adult patients with HoFH.[3] The study enrolled 29 adult patients with a confirmed diagnosis of HoFH who were already on stable background lipid-lowering therapies, which could include statins, ezetimibe, and LDL apheresis.[3] The trial had a total duration of 78 weeks, with a primary efficacy phase lasting 26 weeks.[6]

In this study, Lomitapide was initiated at a low dose and individually titrated upwards based on tolerability to a maximally tolerated dose, with a ceiling of 60 mg per day.[6] The primary efficacy endpoint was the percentage change in LDL-C from baseline to week 26.[3]

The results of the trial were compelling. At the 26-week primary endpoint, treatment with Lomitapide resulted in a mean reduction in LDL-C of 50% from a high baseline mean of 336 mg/dL.[3] An intention-to-treat analysis reported a similarly robust mean reduction of 40%.[3] This substantial lipid-lowering effect was durable, with the mean LDL-C reduction maintained at 38% to 44% at the end of the 78-week study period.[3] In addition to its effect on LDL-C, Lomitapide also produced significant reductions in other atherogenic lipoproteins, including total cholesterol, ApoB, and non-HDL-C.[4] A key finding was that a substantial proportion of these difficult-to-treat patients were able to achieve ambitious LDL-C targets, with over half of the participants achieving an LDL-C level below 100 mg/dL on at least one occasion during the trial.[3]

Long-Term Efficacy: The Extension Trial (NCT00943306)

To assess the durability of efficacy and long-term safety, 19 of the 23 patients who completed the pivotal trial were enrolled in an open-label extension study (NCT00943306).[6] This extension phase provided critical long-term follow-up data, with a median total treatment duration of 5.1 years when combined with the pivotal trial period.[6]

Throughout the extension study, the median maintenance dose of Lomitapide remained consistent at 40 mg per day (range: 20–60 mg), indicating that the dose established during the initial titration phase was generally well-tolerated over the long term.[6] The efficacy observed in the pivotal trial was sustained without attenuation. At week 126 (48 weeks into the extension), the mean LDL-C reduction from the original baseline was -45.5%.[6] This sustained efficacy was observed for the entire duration of the extension trial, demonstrating that tachyphylaxis did not occur. Furthermore, during the long-term follow-up, 74% of patients achieved an LDL-C level <100 mg/dL and 58% achieved an LDL-C level <70 mg/dL on at least one occasion, reinforcing the drug's ability to help patients reach guideline-recommended targets.[6]

Efficacy in Special Populations

The efficacy of Lomitapide has been confirmed in specific populations beyond the cohort of the initial pivotal trial, most notably in pediatric and Japanese patients.

Pediatric Patients (APH-19 study; NCT04681170): Recognizing the critical need for early and aggressive lipid-lowering in HoFH to prevent the progression of atherosclerosis, the APH-19 study was conducted.[24] This open-label, single-arm, Phase 3 trial enrolled 43 pediatric patients with HoFH, aged 5 to 17 years, who were on stable background lipid-lowering therapy.[27] The study demonstrated remarkable efficacy in this younger population. At the 24-week primary endpoint, Lomitapide treatment resulted in a mean LDL-C reduction of -53.5%.[27] This potent effect, which was comparable to or even slightly greater than that observed in adults, was also seen across other lipid parameters, including non-HDL-C (-53.9%) and ApoB (-52.4%).[27] These findings provided the pivotal evidence needed to support the expansion of Lomitapide's indication to include pediatric patients, addressing a major unmet medical need for effective, LDL-receptor-independent therapies in children with HoFH.

Japanese Patients (NCT02173158): To support registration in Japan, a dedicated Phase 3 trial (NCT02173158) was conducted in nine adult Japanese patients with HoFH.[3] The results of this study were highly consistent with the global pivotal trial, showing a statistically significant mean LDL-C reduction of 42% at week 26.[3] This confirmed the drug's efficacy in this ethnic population. Following its approval in Japan, an all-case post-marketing surveillance study was initiated to gather real-world data. An interim analysis of this surveillance study, involving 39 patients, further corroborated the safety and effectiveness of Lomitapide in routine clinical practice in Japan, with a mean LDL-C decrease from 225.9 mg/dL at baseline to 159.4 mg/dL at 12 months.[28]

Real-World Evidence and Clinical Impact

Beyond the controlled environment of clinical trials, real-world observational studies have provided invaluable insights into the effectiveness and clinical impact of Lomitapide in routine practice. A large, multicenter, retrospective observational study encompassing 75 HoFH patients from nine European countries is particularly informative.[7]

This study revealed an even greater degree of LDL-C reduction than reported in the pivotal trial. After a median follow-up of 19 months, patients treated with Lomitapide experienced a mean LDL-C decrease of 60%.[7] This superior effectiveness was achieved at a lower mean daily dose of 20 mg, compared to the 40 mg median dose used in the pivotal trial.[7] This apparent discrepancy suggests that in real-world settings, clinicians may achieve an optimal balance of efficacy and tolerability through more individualized and cautious dose titration, potentially leading to better long-term adherence to the crucial low-fat diet. This finding implies that maximal efficacy may not require pushing to the highest tolerated doses for all patients.

One of the most significant clinical impacts demonstrated in real-world settings is the reduction in the need for LDL apheresis. LDL apheresis is an invasive, time-consuming, and costly procedure that many HoFH patients must undergo every one to two weeks to physically remove LDL-C from their blood.[3] The European observational study found that among patients receiving LDL apheresis at baseline, 36.8% were able to completely discontinue the procedure after initiating Lomitapide therapy.[7] This represents a paradigm shift in patient management, moving beyond the improvement of a surrogate biomarker (LDL-C) to a tangible and profound enhancement of patient quality of life and a significant reduction in the overall burden of care.

While Lomitapide has not been studied in a dedicated cardiovascular outcomes trial, observational data provide a promising signal of cardiovascular protection. The same European study reported a nearly threefold reduction in the rate of Major Adverse Cardiovascular Events (MACE), which fell from 21.2 events per 1000 person-years in the period before Lomitapide initiation to 7.4 events per 1000 person-years after treatment began.[7]

The robust efficacy of Lomitapide has been further solidified by several recent systematic reviews and meta-analyses. One comprehensive meta-analysis of eight studies, including 209 patients, calculated a pooled mean LDL-C reduction of 49.3%.[30] Another analysis of five clinical trials found a mean percentage reduction of 45.1%.[31] These aggregated analyses confirm the potent and consistent LDL-C-lowering effect of Lomitapide across a heterogeneous evidence base, cementing its role as a highly effective therapy for HoFH.[8]

Table 2: Summary of Key Clinical Trials and Real-World Studies for Lomitapide in HoFH

Study Identifier	Study Type	Patient Population (N, Age)	Mean/Median Dose	Duration	Baseline Mean LDL-C	Mean % LDL-C Reduction	Key Clinical Impact	Source(s)
NCT00730236	Phase 3, Open-Label, Single-Arm	29 Adults	40 mg (median)	78 weeks	336 mg/dL	-50% at 26 wks	Pivotal data for regulatory approval.	3
NCT00943306	Long-Term Extension	19 Adults	40 mg (median)	5.1 years (total)	356 mg/dL	-45.5% at 126 wks	Demonstrated durable long-term efficacy.	6
NCT04681170 (APH-19)	Phase 3, Open-Label, Single-Arm	43 Pediatric (5-17 yrs)	Titrated to max tolerated	24 weeks (efficacy)	~290 mg/dL (calculated)	-53.5% at 24 wks	Established efficacy in pediatric patients.	27
NCT02173158	Phase 3, Open-Label, Single-Arm	9 Japanese Adults	Titrated to max tolerated	26 weeks	~300 mg/dL	-42% at 26 wks	Confirmed efficacy in Japanese population.	3
European Observational Study	Retrospective, Real-World	75 Adults	20 mg (mean)	19 months (median)	280.5 mg/dL	-60% at last visit	Showed high real-world effectiveness and reduced need for apheresis.	7

Safety, Tolerability, and Risk Management

The potent efficacy of Lomitapide is accompanied by a significant and well-defined set of safety and tolerability concerns. These adverse effects are largely predictable, as they stem directly from the drug's mechanism of MTP inhibition in the liver and gastrointestinal tract. Consequently, the safe use of Lomitapide is contingent upon a comprehensive and proactive risk management strategy that includes stringent monitoring, patient education, and specific dose adjustments.

Hepatotoxicity Profile (Boxed Warning)

The most significant safety risk associated with Lomitapide is hepatotoxicity, which has led to a boxed warning on its US prescribing information.[1] This risk manifests in two primary ways: elevations in hepatic aminotransferases and the accumulation of hepatic fat (steatosis).

Transaminase Elevations: In the pivotal Phase 3 trial, 10 out of 29 patients (34%) experienced at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to a level three or more times the upper limit of normal (≥3x ULN).[10] These elevations were typically asymptomatic, transient, and manageable with dose reduction or temporary interruption of the drug.[6] Importantly, these transaminase elevations were not accompanied by clinically meaningful increases in total bilirubin or the international normalized ratio (INR), meaning no cases met the criteria for Hy's Law, which would indicate severe drug-induced liver injury.[10] Long-term follow-up data from the extension trial and registries have consistently shown that while transaminase excursions can occur, they are generally reversible and do not herald progressive liver failure.[25]

Hepatic Steatosis (Fatty Liver): An increase in hepatic fat content is an expected on-target effect of Lomitapide, resulting from the inhibition of triglyceride export from hepatocytes.[3] In the pivotal trial, magnetic resonance spectroscopy revealed that the median absolute increase in hepatic fat was 6%, rising from a baseline of 1% to 7% after 26 and 78 weeks of treatment.[6] The theoretical concern is that this drug-induced steatosis could be a risk factor for progressive liver disease, such as steatohepatitis and cirrhosis.[10] However, this concern has been substantially mitigated by long-term safety data. Follow-up studies extending up to 9.5 years have shown that while the increase in liver fat occurs, it tends to be modest, plateaus over time, and is not associated with the development of significant liver fibrosis or cirrhosis.[6] Studies measuring hepatic biomarkers of fibrosis (e.g., Enhanced Liver Fibrosis [ELF] score) and liver stiffness via elastography have found no clinically significant signs of progression to advanced liver disease.[29] This evolving long-term safety profile is highly reassuring, suggesting that the simple steatosis induced by Lomitapide may not carry the same prognostic risk as steatosis from other etiologies, provided that patients are appropriately monitored and other risk factors, such as alcohol use, are controlled.

The Juxtapid REMS Program

Given the significant risk of hepatotoxicity, the U.S. Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) program for Lomitapide, known as the Juxtapid REMS Program.[1] This restricted distribution program is designed to ensure that the benefits of the drug outweigh its risks. Key components of the REMS program include:

• Certification: Only healthcare providers who have been educated on the specific risks of Lomitapide and are certified through the program are permitted to prescribe it.[1]
• Restricted Dispensing: Lomitapide can only be dispensed by pharmacies that are certified in the REMS program.[1]
• Patient Enrollment: Patients must be counseled on the risks, particularly hepatotoxicity, and enrolled in the program.
• Mandatory Monitoring: The program enforces the required schedule of liver function monitoring to ensure early detection of potential liver injury.[10]

Gastrointestinal Adverse Events

Gastrointestinal (GI) adverse events are the most common and frequently dose-limiting side effects of Lomitapide. Their high incidence is a direct and predictable consequence of MTP inhibition in the enterocytes of the small intestine, which leads to impaired chylomicron formation and subsequent malabsorption of dietary fat.[3] In the pivotal trial, GI side effects were reported in 93% of patients.[21]

The most frequently reported symptoms include diarrhea (affecting up to 79% of patients), nausea (65%), dyspepsia, vomiting, abdominal pain and distension, and flatulence.[6] These symptoms are often most severe upon treatment initiation and during dose escalation.[6]

Management of these GI adverse events is a cornerstone of successful Lomitapide therapy and relies on a two-pronged approach:

1. Dietary Modification: Strict adherence to a low-fat diet, with less than 20% of total daily energy intake derived from fat, is mandatory. This reduces the amount of unabsorbed fat in the GI tract, thereby minimizing the primary driver of the symptoms.[36]
2. Gradual Dose Titration: The recommended slow, stepwise dose escalation schedule allows the gastrointestinal tract to adapt to the effects of the drug, improving long-term tolerability.[21]

With these management strategies, the incidence and severity of GI events tend to decrease over time, allowing most patients to continue long-term therapy.6

Other Clinically Significant Risks

Embryo-Fetal Toxicity (Pregnancy Category X): Lomitapide is classified as Pregnancy Category X and is strictly contraindicated during pregnancy due to the risk of causing fetal harm, as demonstrated by teratogenicity in animal studies.[21] Females of reproductive potential must have a negative pregnancy test before initiating therapy and are required to use effective contraception throughout the treatment course. If pregnancy occurs, the drug must be stopped immediately.[21]

Reduced Absorption of Fat-Soluble Vitamins and Fatty Acids: The same mechanism that causes GI side effects—impaired fat absorption—can also lead to deficiencies in fat-soluble vitamins (A, D, E, and K) and essential fatty acids.[10] To mitigate this risk, daily supplementation is a mandatory component of Lomitapide therapy. The prescribed supplement regimen includes 400 international units of vitamin E, at least 200 mg of linoleic acid, 210 mg of alpha-linolenic acid (ALA), 110 mg of eicosapentaenoic acid (EPA), and 80 mg of docosahexaenoic acid (DHA).[21]

Risk of Myopathy with Concomitant Statins: Lomitapide can inhibit the metabolism of certain statins, particularly simvastatin and lovastatin, leading to increased systemic exposure and a heightened risk of myopathy and rhabdomyolysis. Consequently, dose limitations for these specific statins are required when co-administered with Lomitapide.[21]

Galactose Intolerance: The capsule formulation of Lomitapide contains lactose as an excipient. Therefore, it should be avoided in patients with rare hereditary disorders of galactose intolerance, such as Lapp lactase deficiency or glucose-galactose malabsorption, as it may cause diarrhea and malabsorption in these individuals.[17]

Dosing, Administration, and Therapeutic Monitoring

The successful implementation of Lomitapide therapy requires strict adherence to a detailed protocol for dosing, administration, and monitoring. This protocol is designed to maximize efficacy while proactively managing the drug's significant safety and tolerability challenges.

Recommended Dosing and Titration

Treatment with Lomitapide must be initiated at a low dose and escalated gradually to allow for patient adaptation, particularly with respect to gastrointestinal tolerance. The recommended starting dose for all patients is 5 mg taken once daily.[21]

The dose should be titrated according to the following schedule, with the caveat that liver function tests (ALT and AST) must be measured and confirmed to be acceptable prior to any dose increase [21]:

• Step 1: After a minimum of 2 weeks on the 5 mg daily dose, it may be increased to 10 mg once daily.
• Step 2: After a minimum of 4 weeks on the 10 mg daily dose, it may be increased to 20 mg once daily.
• Step 3: After a minimum of 4 weeks on the 20 mg daily dose, it may be increased to 40 mg once daily.
• Step 4: After a minimum of 4 weeks on the 40 mg daily dose, it may be increased to the maximum recommended dose of 60 mg once daily.

The final maintenance dose is not fixed and should be individualized for each patient, taking into account their therapeutic response (i.e., LDL-C reduction) and their ability to tolerate the medication without unacceptable adverse effects.[36]

Dose Adjustments in Specific Populations

Dose adjustments are required for patients with certain comorbidities or those taking specific concomitant medications.

Renal Impairment: In patients with end-stage renal disease (ESRD) who are maintained on dialysis, Lomitapide exposure is increased by approximately 50%. Therefore, the maximum recommended dose in this population is reduced to 40 mg daily.[21]

Hepatic Impairment: Lomitapide is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C) or those with active liver disease, including unexplained persistent elevations in liver function tests.[36] For patients with mild baseline hepatic impairment (Child-Pugh class A), the maximum dose should not exceed

40 mg daily.[21]

Concomitant Weak CYP3A4 Inhibitors: Co-administration of Lomitapide with weak inhibitors of CYP3A4 (such as atorvastatin, oral contraceptives, or fluconazole) can approximately double the systemic exposure to Lomitapide. In such cases, the dose of Lomitapide should be reduced by half, and the maximum daily dose must not exceed 30 mg.[10]

Administration and Patient Counseling

Effective patient counseling is critical for ensuring adherence and safety. The following administration instructions must be clearly communicated:

• Diet: Patients must initiate and maintain a low-fat diet that provides less than 20% of total daily energy from fat. This is essential for managing GI side effects.[36]
• Timing of Dose: Lomitapide should be taken once daily on an empty stomach, at least 2 hours after the evening meal. It should be swallowed with a full glass of water. Taking the medication with food can significantly increase the risk and severity of GI adverse reactions.[21]
• Capsule Integrity: The capsules must be swallowed whole and should not be opened, split, chewed, dissolved, or crushed.[21]
• Mandatory Supplementation: Patients must be instructed to take daily supplements containing vitamin E and essential fatty acids (linoleic acid, ALA, EPA, and DHA) as prescribed to prevent nutritional deficiencies.[21]
• Dietary Restrictions: Patients must be counseled to completely avoid consuming grapefruit and grapefruit juice, as they are potent inhibitors of CYP3A4 and can dangerously increase Lomitapide levels.[36] Alcohol consumption should be strictly limited to no more than one alcoholic beverage per day to minimize the risk of hepatic fat accumulation and liver injury.[21]

Monitoring Requirements

Vigilant laboratory monitoring is a non-negotiable component of Lomitapide therapy.

• Baseline Assessments: Before a patient starts treatment, the following baseline tests are required:
• A full liver function panel, including ALT, AST, alkaline phosphatase, and total bilirubin.[21]
• A negative pregnancy test for all females of reproductive potential.[21]
• Ongoing Monitoring:
• Liver Function: ALT and AST levels must be monitored frequently: monthly during the first year of treatment, and at least every 3 months thereafter. Monitoring is also required prior to every dose increase.[21]
• Dose Modification for LFT Elevations: A clear, protocolized approach must be followed if transaminase levels rise. If ALT or AST levels are confirmed to be between ≥3x and <5x ULN, the dose should be reduced. If levels rise to ≥5x ULN, or if elevations are accompanied by symptoms of liver injury or increased bilirubin, dosing should be withheld or permanently discontinued, and a full investigation into the cause should be initiated.[21]

Drug Interaction Profile

Lomitapide's pharmacokinetic profile, characterized by its near-exclusive reliance on CYP3A4 for metabolism and its effects on the P-glycoprotein transporter, results in a high potential for clinically significant drug-drug interactions. Careful management of concomitant medications is a critical aspect of its safe use.

Interactions via Cytochrome P450 3A4 (CYP3A4)

Lomitapide as a CYP3A4 Substrate: Lomitapide is extensively metabolized by CYP3A4, making its plasma concentrations highly sensitive to drugs that modulate this enzyme's activity.[5]

• Strong and Moderate CYP3A4 Inhibitors: Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) or moderate inhibitors (e.g., erythromycin, diltiazem, verapamil) is CONTRAINDICATED. These agents can dramatically increase Lomitapide exposure, elevating the risk of severe toxicity, particularly hepatotoxicity.[3] Grapefruit juice, a well-known moderate CYP3A4 inhibitor, must also be completely avoided.[3]
• Weak CYP3A4 Inhibitors: Co-administration with weak CYP3A4 inhibitors (e.g., atorvastatin, oral contraceptives, amiodarone, fluconazole) can increase Lomitapide exposure by approximately 2-fold.[3] When such an agent is necessary, the dose of Lomitapide must be reduced by 50%, and the maximum daily dose should not exceed 30 mg.[10]
• CYP3A4 Inducers: While not explicitly contraindicated, drugs that induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) are expected to significantly decrease the plasma concentration of Lomitapide, which could lead to a loss of therapeutic efficacy.

Lomitapide as a CYP3A4 Inhibitor: Lomitapide itself is a weak inhibitor of CYP3A4.[1] This means it has the potential to increase the plasma concentrations of other drugs that are substrates of this enzyme. This effect is particularly relevant for certain statins, as discussed below.[3]

Interactions via P-glycoprotein (P-gp)

Lomitapide is also an inhibitor of the P-glycoprotein (P-gp) efflux transporter, which is found in the intestine, kidneys, and other tissues, and plays a role in limiting the absorption and promoting the excretion of many drugs.[1] By inhibiting P-gp, Lomitapide can increase the absorption and systemic exposure of P-gp substrates. Clinically relevant examples include digoxin, colchicine, aliskiren, and dabigatran.[3] When co-administering Lomitapide with a P-gp substrate, a dose reduction of the substrate should be considered, and patients should be monitored for signs of increased drug effect or toxicity.[3]

Specific Drug Interactions

Several specific drug interactions warrant particular attention:

• Warfarin: Lomitapide increases the plasma concentrations of warfarin, potentially leading to over-anticoagulation and an increased risk of bleeding. The international normalized ratio (INR) must be monitored regularly, particularly after initiating Lomitapide or adjusting its dose, and the warfarin dose should be adjusted as clinically indicated.[21]
• Simvastatin and Lovastatin: Lomitapide approximately doubles the systemic exposure of simvastatin and is expected to have a similar effect on lovastatin, both of which are sensitive CYP3A4 substrates. This increases the risk of statin-induced myopathy. To manage this risk, the dose of simvastatin should be reduced by 50% when initiating Lomitapide, and the maintenance dose should not exceed 20 mg daily (or 40 mg daily for patients with a history of tolerating 80 mg).[3] Similar caution and potential dose reduction should be applied for lovastatin.
• Bile Acid Sequestrants: Agents like cholestyramine, colesevelam, and colestipol can bind to other drugs in the GI tract and prevent their absorption. To avoid this interaction, bile acid sequestrants should be administered at least 4 hours before or 4 hours after the Lomitapide dose.[39]

Table 3: Lomitapide Drug Interaction and Management Guide

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Strong/Moderate CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, grapefruit juice)	Inhibition of Lomitapide metabolism	Large increase in Lomitapide exposure; high risk of toxicity (hepatotoxicity)	CONTRAINDICATED	3
Weak CYP3A4 Inhibitors (e.g., atorvastatin, fluconazole, verapamil, oral contraceptives)	Inhibition of Lomitapide metabolism	~2-fold increase in Lomitapide exposure; increased risk of toxicity	Reduce Lomitapide dose by 50%; Do not exceed 30 mg daily.	3
Warfarin	Inhibition of warfarin metabolism	Increased warfarin exposure; increased INR and bleeding risk	Monitor INR frequently, especially after Lomitapide dose changes. Adjust warfarin dose as needed.	21
Simvastatin / Lovastatin	Lomitapide inhibits CYP3A4-mediated statin metabolism	Increased statin exposure; increased risk of myopathy	Limit simvastatin dose (e.g., ≤20-40 mg/day). Consider lovastatin dose reduction.	3
P-gp Substrates (e.g., digoxin, colchicine, aliskiren)	Lomitapide inhibits P-gp efflux transporter	Increased absorption and exposure of the P-gp substrate	Consider dose reduction of the P-gp substrate. Monitor for increased effects/toxicity.	3
Bile Acid Sequestrants (e.g., cholestyramine, colesevelam)	Binding of Lomitapide in the GI tract	Reduced Lomitapide absorption and efficacy	Separate administration times by at least 4 hours.	39

Regulatory Status and Conclusion

Global Regulatory Approvals

Lomitapide's path to market was paved by its designation as an orphan drug, a status granted to therapies for rare diseases. In the United States, the FDA granted Lomitapide Orphan Drug designation for the treatment of HoFH on October 23, 2007.[4] This was a critical step that provided incentives and a focused regulatory pathway for its development.

Following a positive 13-to-2 vote recommending approval from its Endocrinologic and Metabolic Drugs Advisory Committee in October 2012, the U.S. FDA granted full approval to Lomitapide (Juxtapid) on December 21, 2012.[4] The approved indication was as an adjunct to a low-fat diet and other lipid-lowering treatments to reduce LDL-C, total cholesterol, ApoB, and non-HDL-C in patients with HoFH.[4]

In Europe, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, leading to the European Medicines Agency (EMA) granting marketing authorization for Lomitapide (Lojuxta) in July 2013.[1] The European indication is similar, for use as an adjunct therapy in adult patients with HoFH, with the recommendation that the diagnosis be confirmed by genetic testing whenever possible.[45] The EMA had previously granted orphan designation for Lomitapide for the treatment of familial chylomicronaemia in 2010, reflecting its potential utility in other severe lipid disorders, though HoFH became its primary approved indication.[47]

Lomitapide has subsequently been approved in numerous other jurisdictions worldwide. In Japan, it also received orphan drug designation in September 2013 and underwent an expedited review process, gaining approval in September 2016 after just 8.8 months of review, with a market launch in December 2016.[13] As of 2016, it was approved in 38 countries.[13]

Expert Synthesis and Concluding Remarks

Lomitapide represents a landmark therapeutic achievement in the management of Homozygous Familial Hypercholesterolemia. It provides a potent and mechanistically unique solution to the central pathophysiological challenge of this disease: the inability to clear LDL-C via the LDL-receptor pathway. By directly inhibiting the production of atherogenic lipoproteins, Lomitapide can achieve profound LDL-C reductions, often in the range of 50% or more, a feat that is frequently unattainable with the combination of all other available therapies in this patient population.

The clinical value of Lomitapide extends beyond its impact on surrogate lipid endpoints. Compelling real-world evidence has demonstrated its ability to significantly reduce or even eliminate the need for burdensome and invasive LDL apheresis, fundamentally altering the treatment paradigm and improving the quality of life for many patients. Furthermore, while definitive cardiovascular outcome data are lacking, observational studies have provided a promising signal for a reduction in major adverse cardiovascular events, consistent with the known benefits of aggressive LDL-C lowering.

However, this profound efficacy is inextricably linked to a challenging safety and tolerability profile. The on-target MTP inhibition that drives its therapeutic benefit also directly causes the primary adverse events: gastrointestinal intolerance due to fat malabsorption and hepatic steatosis with a risk of transaminase elevations. These are not idiosyncratic toxicities but predictable, mechanism-based effects.

Consequently, the successful and safe use of Lomitapide is not a simple matter of prescribing a medication. It demands the implementation of a comprehensive, multi-faceted management program. This program requires rigorous patient selection, meticulous and ongoing patient education on a strict low-fat diet, a slow and patient-guided dose titration, proactive management of side effects, mandatory nutritional supplementation to prevent deficiencies, and vigilant laboratory monitoring of liver function. The extensive and complex drug interaction profile, particularly concerning the CYP3A4 pathway, further reinforces that this drug should only be prescribed by clinicians with expertise in lipidology and a thorough understanding of its pharmacology.

In final assessment, Lomitapide is not a therapy for general hypercholesterolemia, but for its approved indication in HoFH, it remains an indispensable and often life-altering tool. Within this specific context, its risk-benefit profile is strongly positive, provided that both clinicians and patients are fully committed to the intensive management protocol it necessitates. The accumulation of long-term safety data, which has been increasingly reassuring regarding the risk of progressive liver disease, has further solidified its role as a cornerstone of long-term combination therapy for one of the most severe and challenging inherited disorders of lipid metabolism.

Works cited

1. Lomitapide | C39H37F6N3O2 | CID 9853053 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lomitapide
2. Lomitapide (AEGR-733) | MTP Inhibitor - MedchemExpress.com, accessed September 1, 2025, https://www.medchemexpress.com/Lomitapide.html
3. Lomitapide: a review of its clinical use, efficacy, and tolerability | CE, accessed September 1, 2025, https://www.dovepress.com/lomitapide-a-review-of-its-clinical-use-efficacy-and-tolerability-peer-reviewed-fulltext-article-CE
4. Lomitapide - Wikipedia, accessed September 1, 2025, https://en.wikipedia.org/wiki/Lomitapide
5. Lomitapide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 1, 2025, https://go.drugbank.com/drugs/DB08827
6. Long-Term Efficacy and Safety of the Microsomal Triglyceride ..., accessed September 1, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028208
7. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study - Oxford Academic, accessed September 1, 2025, https://academic.oup.com/eurjpc/article/29/5/832/6491248
8. Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review - IMR Press, accessed September 1, 2025, https://www.imrpress.com/journal/RCM/23/5/10.31083/j.rcm2305151/htm
9. Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia - IMR Press, accessed September 1, 2025, https://www.imrpress.com/journal/RCM/15/1/10.3909/ricm0702/pdf
10. About Juxtapid | HCP, accessed September 1, 2025, https://www.juxtapid.com/hcp/about-juxtapid
11. Lomitapide free base | AEGR-733 | BMS201038 | CAS#182431-12-5 | MTP inhibitor, accessed September 1, 2025, https://www.medkoo.com/products/7249
12. pubchem.ncbi.nlm.nih.gov, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lomitapide#:~:text=Lomitapide%20is%20a%20member%20of,%2Dfluorene%2D9%2Dcarboxamide.
13. AEGERION PHARMACEUTICALS K.K., accessed September 1, 2025, https://www.jetro.go.jp/ext_images/usa/aegerion.pdf
14. Lomitapide - brand name list from Drugs.com, accessed September 1, 2025, https://www.drugs.com/ingredient/lomitapide.html
15. Lomitapide 182431-12-5 | TCI AMERICA - Tokyo Chemical Industry, accessed September 1, 2025, https://www.tcichemicals.com/US/en/p/L0298
16. Lomitapide (AEGR 773, BMS 201038, CAS Number: 182431-12-5) | Cayman Chemical, accessed September 1, 2025, https://www.caymanchem.com/product/10009610/lomitapide
17. Lomitapide - StatPearls - NCBI Bookshelf, accessed September 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560849/
18. Lomitapide: a review of its clinical use, efficacy, and tolerability - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6615460/
19. Lomitapide metabolite M4 | C25H30F3N3O | CID 9911388 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/9911388
20. Lomitapide metabolite M11 | C39H37F6N3O3 | CID 165411961 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lomitapide-metabolite-M11
21. JUXTAPID (lomitapide) - accessdata.fda.gov, accessed September 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf
22. High Cholesterol Completed Phase 2 Trials for Lomitapide (DB08827) | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/indications/DBCOND0037835/clinical_trials/DB08827?phase=2&status=completed
23. Lomitapide Completed Phase 2 Trials for High Cholesterol Treatment | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB08827/clinical_trials?conditions=DBCOND0037835&phase=2&purpose=treatment&status=completed
24. Lomitapide Completed Phase 3 Trials for Homozygous Familial Hypercholesterolaemia (HoFH) Treatment | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB08827/clinical_trials?conditions=DBCOND0135612&phase=3&purpose=treatment&status=completed
25. Long-term hepatic safety of lomitapide in homozygous familial ..., accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/36520008/
26. Lomitapide Significantly Lowers LDL-C in Patients With HoFH, Study Finds, accessed September 1, 2025, https://www.ajmc.com/view/lomitapide-significantly-lowers-ldlc-in-patients-with-hofh-study-finds
27. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39426393/
28. Full article: Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan, accessed September 1, 2025, https://www.tandfonline.com/doi/full/10.2217/fca-2023-0136
29. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/357476647_Efficacy_and_safety_of_lomitapide_in_homozygous_familial_hypercholesterolaemia_the_pan-European_retrospective_observational_study
30. Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in ..., accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/40856940/
31. Efficacy and safety of lomitapide, a microsomal triglyceride transfer protein inhibitor, in homozygous familial hypercholesterolemia: A systematic review and meta-analysis of clinical trials - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/394013789_Efficacy_and_safety_of_lomitapide_a_microsomal_triglyceride_transfer_protein_inhibitor_in_homozygous_familial_hypercholesterolemia_A_systematic_review_and_meta-analysis_of_clinical_trials
32. Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/360281429_Efficacy_and_Safety_of_Lomitapide_in_Homozygous_Familial_Hypercholesterolaemia_A_Systematic_Review
33. Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39077612/
34. Juxtapid (lomitapide) MCP-155 - Molina Healthcare, accessed September 1, 2025, https://www.molinahealthcare.com/providers/tx/PDF/Marketplace/Pharmacy/RXSC2019120.pdf
35. Lomitapide Hepatic Safety: A Long-Term Retrospective Analysis in Patients with Homozygous Familial Hypercholesterolaemia - DOI, accessed September 1, 2025, https://doi.org/10.1016/j.jacl.2023.05.046
36. Lomitapide Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 1, 2025, https://www.drugs.com/dosage/lomitapide.html
37. Lojuxta | European Medicines Agency (EMA), accessed September 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta
38. Reference ID: 3934821 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed September 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203858s015lbl.pdf
39. Lomitapide: MedlinePlus Drug Information, accessed September 1, 2025, https://medlineplus.gov/druginfo/meds/a614008.html
40. Lomitapide (oral route) - Side effects & dosage - Mayo Clinic, accessed September 1, 2025, https://www.mayoclinic.org/drugs-supplements/lomitapide-oral-route/description/drg-20060682
41. Juxtapid (lomitapide) dosing, indications, interactions, adverse effects, and more, accessed September 1, 2025, https://reference.medscape.com/drug/juxtapid-lomitapide-999804
42. Search Orphan Drug Designations and Approvals - FDA, accessed September 1, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=245907
43. Juxtapid (lomitapide) FDA Approval History - Drugs.com, accessed September 1, 2025, https://www.drugs.com/history/juxtapid.html
44. FDA Approves Lomitapide for HoFH | National Lipid Association Online, accessed September 1, 2025, https://www.lipid.org/nla/fda-approves-lomitapide-hofh
45. Lojuxta | European Medicines Agency - ClinPGx, accessed September 1, 2025, https://www.clinpgx.org/literature/15103647
46. Annotation of EMA Label for lomitapide and APOB, LDLR, PCSK9 - PharmGKB, accessed September 1, 2025, https://www.clinpgx.org/labelAnnotation/PA166121250
47. EU/3/10/823 - orphan designation for treatment of familial chylomicronaemia, accessed September 1, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu310823